Paloma Partners’s GenMark Diagnostics, Inc GNMK Stock Holding History

Paloma Partners’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-13,130	Closed	-$187K	–	2449
2020 Q3	$187K	Buy	+13,130	New	+$201K	﹤0.01%	1786
2020 Q2	–	Sell	-30,301	Closed	-$125K	–	2317
2020 Q1	$125K	Buy	+30,301	New	+$142K	0.01%	1005
2019 Q2	–	Sell	-11,262	Closed	-$80K	–	2332
2019 Q1	$80K	Sell	11,262 -5,238	-32%	-$34.5K	﹤0.01%	1610
2018 Q4	$80K	Buy	+16,500	New	+$85.9K	﹤0.01%	1133
2018 Q1	–	Sell	-13,818	Closed	-$58K	–	2372
2017 Q4	$58K	Buy	+13,818	New	+$83.2K	﹤0.01%	1815

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Paloma Partners's GNMK Position: Q4 2020 in Review

Paloma Partners sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2020, closing a stake of 13,130 shares — an estimated $187K sold.

Paloma Partners first reported a position in GNMK in Q4 2017 and held it in 5 quarters. The position peaked at $187K in Q3 2020. 151 funds tracked by Wall St. Rank hold GNMK as of Q4 2020.

Paloma Partners reported no remaining GenMark Diagnostics, Inc position as of Q4 2020 after selling out during the quarter.
Paloma Partners sold 13,130 GenMark Diagnostics, Inc shares in Q4 2020, an estimated $187K.
Paloma Partners first reported a position in GenMark Diagnostics, Inc in Q4 2017 and held it in 5 quarters.
Paloma Partners's GenMark Diagnostics, Inc position peaked at $187K in Q3 2020.
151 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.